These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27597724)

  • 1. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
    Ashtari F; Toghianifar N; Zarkesh-Esfahani SH; Mansourian M
    Neurol Res; 2016 Oct; 38(10):888-92. PubMed ID: 27597724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
    Ashtari F; Toghianifar N; Zarkesh-Esfahani SH; Mansourian M
    Neuroimmunomodulation; 2015; 22(6):400-4. PubMed ID: 26401986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
    Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M
    J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
    Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
    J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of daily high-dose vitamin D
    Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
    Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
    Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
    Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
    J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
    Bhargava P; Cassard S; Steele SU; Azevedo C; Pelletier D; Sugar EA; Waubant E; Mowry EM
    Contemp Clin Trials; 2014 Nov; 39(2):288-93. PubMed ID: 25311447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
    Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
    Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
    J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.
    Jongen PJ; Sindic C; Carton H; Zwanikken C; Lemmens W; Borm G;
    J Neurol; 2010 Apr; 257(4):584-9. PubMed ID: 19921303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis.
    Golan D; Staun-Ram E; Glass-Marmor L; Lavi I; Rozenberg O; Dishon S; Barak M; Ish-Shalom S; Miller A
    Brain Behav Immun; 2013 Aug; 32():180-5. PubMed ID: 23665342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
    Holmøy T; Røsjø E; Zetterberg H; Blennow K; Lindstrøm JC; Steffensen LH; Kampman MT
    Acta Neurol Scand; 2019 Feb; 139(2):172-176. PubMed ID: 30317548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
    Sharafaddinzadeh N; Moghtaderi A; Kashipazha D; Majdinasab N; Shalbafan B
    Mult Scler; 2010 Aug; 16(8):964-9. PubMed ID: 20534644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.